Sagimet Biosciences Inc. (SGMT): auditor change — Sagimet appoints KPMG as auditor, dismisses Deloitte; no disagreements reported

Sagimet Biosciences Inc.

Audit Committee and Board approved KPMG as independent auditor for FY 2025 and dismissed Deloitte effective August 18, 2025.
Deloitte's audit reports for 2023 and 2024 contained no adverse opinion or qualification.
No disagreements with Deloitte occurred in the past two fiscal years or interim period through August 18, 2025.
KPMG had not been previously consulted on accounting principles or audits prior to engagement.
Deloitte provided a letter agreeing with disclosure, attached as Exhibit 16.1.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 1.0

Sagimet Biosciences Inc. dismissed Deloitte & Touche LLP as its auditor.

Action: dismissal
Auditor: Deloitte & Touche LLP

Exact text from the filing

iscal year ending December 31, 2025 and related interim periods and, concurrently, (ii) the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm, effective immediately.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 1.0

Sagimet Biosciences Inc. engaged KPMG LLP as its auditor.

Action: engagement
Auditor: KPMG LLP

Exact text from the filing

i) the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 and related interim periods and, concurrently, (ii) the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm, effective immediately. The audit reports of Deloitte on the Company’s financial statements as of December 31, 2024 and December 31, 2023, did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles. Furthermore, during the two most recent fiscal years ended December 31, 2024 and December 31, 2023, and the subsequent interim period through August 18, 2025, there were no disagreements with Deloitte on any matter of accounting principles or practices, financial statement disclosure, or a

View on SEC.gov

21 auditor changes filed in the last 30 days. Browse all auditor changes →

Sagimet Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-081630

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.